Skip to content

Prune Consumption and Bone Health in Young Women Using Hormonal Contraceptives

The Impact of Consuming California Dried Plums on Bone Health of Young Women Using Hormonal Contraceptives

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04785131
Enrollment
90
Registered
2021-03-05
Start date
2019-11-30
Completion date
2024-12-30
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis Risk

Keywords

Prune, Bone health, Oral contraceptives, Women health

Brief summary

The primary objective of this study is to determine if 12 months of consuming 50 grams of dried plum daily will prevent bone loss or augment bone accrual of young adult oral contraceptive (OC) users.

Detailed description

Eligible participants will be assigned among three groups 1) control non-OC users, 2) control OC users, and 3) dried plum OC users. OC users will be randomly allocated to the dried plum OC group, which will consume 50 g dried plum daily for 12 months, or a control group, for which dried plums will not be allowed and no control food will be provided.

Interventions

OTHERPrune

daily consumption of 50 grams prune.

Sponsors

San Diego State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-25

Exclusion criteria

* Metabolic bone disease, renal disease, cancer, CVD, diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease or other chronic diseases, heavy smoking (more than twenty cigarettes/day) and current use of any prescription medications known to alter bone and calcium metabolism * Regularly consumed dried plum or prune juice

Design outcomes

Primary

MeasureTime frameDescription
Changes in bone mineral density from baseline to 12 monthsAt baseline, at 12 monthsBone density measurements with DXA

Secondary

MeasureTime frameDescription
Changes from baseline in bone specific alkaline phosphatase at 6 months and 12 monthsAt baseline, at 6 months, at 12 monthsBone biomarkers measurements with ELISA

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026